All Photos(1)

Documents

Y0000271

Oxaliplatin

Name: Oxaliplatin
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N′)[ethanedioata(2--)-O,O’]platinum

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₈H₁₄N₂O₄Pt

CAS Number:

61825-94-3

Molecular Weight:

397.29

MDL number:

MFCD00866327

UNSPSC Code:

41116107

PubChem Substance ID:

329830895

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

oxaliplatin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1O[Pt]OC1=O.N[C@@H]2CCCC[C@H]2N

InChI

1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1

InChI key

ZROHGHOFXNOHSO-BNTLRKBRSA-L

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Oxaliplatin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1481226

1481215

1481237

1481248

1481306

Oxaliplatin System Suitability, United States Pharmacopeia (USP) Reference Standard

1481260

PHR2545

Pictograms

GHS08,GHS05

Signal Word

Danger

Hazard Statements

H317,H318,H334,H341,H351,H360FD,H362,H372

Precautionary Statements

P260 - P263 - P280 - P302 + P352 - P305 + P351 + P338 - P308 + P313

Hazard Classifications

Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge.

S M E Engelen et al.

European journal of cancer (Oxford, England : 1990), 49(10), 2311-2320 (2013-04-11)

The purpose of this multicenter cohort study was to evaluate whether a differentiated treatment of primary rectal cancer based on magnetic resonance imaging (MRI) can reduce the number of incomplete resections and local recurrences and improve recurrence-free and overall survival.

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Bernard Nordlinger et al.

The Lancet. Oncology, 14(12), 1208-1215 (2013-10-15)

Previous results of the EORTC intergroup trial 40983 showed that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) increases progression-free survival (PFS) compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. Here we present

Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment.

Noriho Iida et al.

Science (New York, N.Y.), 342(6161), 967-970 (2013-11-23)

The gut microbiota influences both local and systemic inflammation. Inflammation contributes to development, progression, and treatment of cancer, but it remains unclear whether commensal bacteria affect inflammation in the sterile tumor microenvironment. Here, we show that disruption of the microbiota

A role for Myh1 in DNA repair after treatment with strand-breaking and crosslinking chemotherapeutic agents.

Kristina Jansson et al.

Environmental and molecular mutagenesis, 54(5), 327-337 (2013-05-17)

The highly conserved DNA glycosylase MutY is implicated in repair of oxidative DNA damage, in particular in removing adenines misincorporated opposite 7,8-dihydro-8-oxoguanine (8-oxo-G). The MutY homologues (MutYH) physically associate with proteins implicated in replication, DNA repair, and checkpoint signaling, specifically

Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.

Roser Velasco et al.

Journal of neurology, neurosurgery, and psychiatry, 85(4), 392-398 (2013-07-03)

Peripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers that may help to identify patients at risk of developing

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service